<DOC>
	<DOCNO>NCT01254227</DOCNO>
	<brief_summary>This study evaluate efficacy safety deferasirox combination deferoxamine follow deferasirox monotherapy patient severe iron overload due chronic blood transfusion .</brief_summary>
	<brief_title>Efficacy Safety Deferasirox Combination With Deferoxamine Followed Deferasirox Monotherapy Severe Cardiac Iron Overload</brief_title>
	<detailed_description />
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>Patients βthalassemia major DiamondBlackfan anemia ( DBA ) congenital sideroblastic anemia chronic transfusion therapy Myocardial T2* value ≥ 5 &lt; 10 m Left ventricular ejection fraction ( LVEF ) ≥ 56 % determine Magnetic resonance imaging ( MRI ) Lifetime history least 50 unit red blood cell transfusion , must receive least ≥ 8 units/yr red blood cell transfusion Patients clinical symptom cardiac dysfunction ( shortness breath rest exertion , orthopnea , exercise intolerance , low extremity edema , arrhythmia ) Patients unable undergo study assessment include MRI Patients serum creatinine great Upper limit normal ULN ) range significant proteinuria indicate urinary protein/creatinine ratio ( UPCR ) ≥1.0 mg/mg nonfirst void urine sample baseline . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Cardiac iron overload ,</keyword>
	<keyword>deferasirox ,</keyword>
	<keyword>deferoxamine</keyword>
</DOC>